Siddique Muhammad Shoaib, Shoaib Sana, Saad Alvia, Iqbal Hamna Javed, Durrani Noureen
Dr. Muhammad ShoaibSiddique, FCPS Gastroenterology. Consultant Gastroenterologists, Memon Medical Institute & Hospital, Karachi, Pakistan.
Dr. Sana Shoaib, FCPS Medicine. Consultant Medicine, Memon Medical Institute & Hospital, Karachi, Pakistan.
Pak J Med Sci. 2017 Jul-Aug;33(4):813-817. doi: 10.12669/pjms.334.12785.
To determineRapid & End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C at tertiary care hospital.
It was an observational study conducted at Memon Medical Institute from January 2016 to July 2017. The inclusion criteria for patients was 18 years of age or older, having chronic infection with HCV. Total=201 received sofosbuvir with or without interferon in our OPDs. Patients were categorized into Treatment naïve, treatment experienced and decompensated chronic liver disease. Pregnant patients and those not willing to participate were excluded. Initially genotyping and Quantitative HCV RNA test was done.
A total of 201 subjects were included in the study with mean age of the patients was 46.22± 14.41 years. Of 201 patients, n= 131 (65.2%) chronic hepatitis C, compensated cirrhosis n= 47(23.4%), and with decompensated cirrhosis n=23(11.4%). Most commonly genotype 3 n= 180 (89.6%) was present followed by genotype 1 n=9(4.5%), genotype 2 n=1(0.5%), genotype 4 n=1(0.5%). Of patients with genotype 3, 123 received dual therapy and 57 were given triple therapy. After one month of therapy HCV RNA by PCR, 200(99.5%) achieved RVR, 199(99%) achieved ETR and SVR achieved in 178(88.5%) while remaining 1 patient did not achieved RVR, 2 ETR and 12 patients did not achieved SVR and remaining 11 SVR lost follow up.
Sofosbuvir has shown to be very effective andsuccessfulwith achievement of virological response with little or no resistance in all genotypes mainly genotype 3 treated in our study population. The promising results of our study will aid in better outcomes and therefore help in eradication of the virus.
确定在三级医疗机构接受索磷布韦治疗的慢性丙型肝炎患者的快速及最终治疗反应。
这是一项于2016年1月至2017年7月在梅蒙医学院进行的观察性研究。患者的纳入标准为年龄在18岁及以上，患有丙型肝炎病毒慢性感染。共有201例患者在我们的门诊接受了索磷布韦治疗，无论是否联合使用干扰素。患者被分为初治患者、经治患者和失代偿期慢性肝病患者。排除孕妇和不愿参与者。最初进行了基因分型和丙型肝炎病毒定量核糖核酸检测。
共有201名受试者纳入研究，患者的平均年龄为46.22±14.41岁。在201例患者中，131例（65.2%）为慢性丙型肝炎，47例（23.4%）为代偿期肝硬化，23例（11.4%）为失代偿期肝硬化。最常见的基因型为3型，共180例（89.6%），其次是1型9例（4.5%）、2型1例（0.5%）、4型1例（0.5%）。在3型基因型患者中，123例接受了联合治疗，57例接受了三联治疗。治疗1个月后通过聚合酶链反应检测丙型肝炎病毒核糖核酸，200例（99.5%）实现快速病毒学应答，199例（99%）实现早期病毒学应答，178例（88.5%）实现持续病毒学应答，而其余1例未实现快速病毒学应答，2例未实现早期病毒学应答，12例未实现持续病毒学应答，其余11例持续病毒学应答患者失访。
在我们的研究人群中，索磷布韦已显示出非常有效且成功，在所有基因型尤其是3型基因型中实现了病毒学应答，几乎没有或没有耐药性。我们研究的良好结果将有助于取得更好的治疗效果，从而有助于根除该病毒。
